Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

There is promise for PD-1 checkpoint inhibitors, as well as CTLA-4 plus PD-L1 combination strategies in the treatment of patients with penile cancer, says Sonpavde.

Sonpavde says that he expects activity with immunotherapy regimens because PD-L1 is overexpressed in over 50% of tumors, and about 50% of patients have disease derived from HPV.